Lipoprotein-associated phospholipase A2

review and recommendation of a clinical cut point for adults.

Richard B. Lanman, Robert L. Wolfert, James K. Fleming, Allan S Jaffe, William L. Roberts, G. Russell Warnick, Joseph P. McConnell

Research output: Contribution to journalArticle

46 Citations (Scopus)

Abstract

Recently, several epidemiologic studies have demonstrated an association between plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) concentration and risk of subsequent cardiovascular events. Several major commercial and reference laboratories across the United States are now offering Lp-PLA2 testing for clinical use to evaluate cardiovascular risk and as a guide to intensity of therapy in individuals at intermediate risk for developing coronary heart disease. Each laboratory has established its own cut points, or "decision values," for Lp-PLA2, which vary from the 50th to the 95th percentile values of individual populations tested at each site. Uniform reporting of cut points has not been achieved. The purpose of this manuscript is to recommend appropriate decision values for Lp-PLA2, endorsed by a consensus panel of laboratorians and clinicians from the major laboratories where the test is performed. These coauthors possess considerable experience with assessment of cardiovascular risk marker decision values in general and are familiar with the validation of the Lp-PLA2 immunoassay and the Lp-PLA2 clinical studies conducted thus far. An ideal risk marker, studied in an ideal population, might yield a consistent cut point associated with a sudden increase in cardiovascular risk. While acknowledging that additional studies will be required to test and refine the recommended decision value, this article reviews the most current information with which to provide guidance to practicing clinicians regarding Lp-PLA2 levels. Since several studies have demonstrated increased risk associated with the second and third tertiles vs. the first tertile for Lp-PLA2, the 50th percentile cut point (235 ng/mL) is recommended as a conservative cut point associated with increased risk for cardiovascular disease. This cut point is not proposed as a treatment target, but rather as a level above which clinicians should consider a patient to be at higher risk for cardiovascular events, independent of established risk factors, high- and low-density lipoprotein cholesterol, and high-sensitivity C-reactive protein.

Original languageEnglish (US)
Pages (from-to)138-143
Number of pages6
JournalPreventive Cardiology
Volume9
Issue number3
DOIs
StatePublished - Jun 2006
Externally publishedYes

Fingerprint

1-Alkyl-2-acetylglycerophosphocholine Esterase
Immunoassay
C-Reactive Protein
LDL Cholesterol
Population
Coronary Disease
Epidemiologic Studies
Cardiovascular Diseases

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Public Health, Environmental and Occupational Health

Cite this

Lanman, R. B., Wolfert, R. L., Fleming, J. K., Jaffe, A. S., Roberts, W. L., Warnick, G. R., & McConnell, J. P. (2006). Lipoprotein-associated phospholipase A2: review and recommendation of a clinical cut point for adults. Preventive Cardiology, 9(3), 138-143. https://doi.org/10.1111/j.1520-037X.2006.05547.x

Lipoprotein-associated phospholipase A2 : review and recommendation of a clinical cut point for adults. / Lanman, Richard B.; Wolfert, Robert L.; Fleming, James K.; Jaffe, Allan S; Roberts, William L.; Warnick, G. Russell; McConnell, Joseph P.

In: Preventive Cardiology, Vol. 9, No. 3, 06.2006, p. 138-143.

Research output: Contribution to journalArticle

Lanman, Richard B. ; Wolfert, Robert L. ; Fleming, James K. ; Jaffe, Allan S ; Roberts, William L. ; Warnick, G. Russell ; McConnell, Joseph P. / Lipoprotein-associated phospholipase A2 : review and recommendation of a clinical cut point for adults. In: Preventive Cardiology. 2006 ; Vol. 9, No. 3. pp. 138-143.
@article{3bd075358d2c4f29bebcf14bc67d626d,
title = "Lipoprotein-associated phospholipase A2: review and recommendation of a clinical cut point for adults.",
abstract = "Recently, several epidemiologic studies have demonstrated an association between plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) concentration and risk of subsequent cardiovascular events. Several major commercial and reference laboratories across the United States are now offering Lp-PLA2 testing for clinical use to evaluate cardiovascular risk and as a guide to intensity of therapy in individuals at intermediate risk for developing coronary heart disease. Each laboratory has established its own cut points, or {"}decision values,{"} for Lp-PLA2, which vary from the 50th to the 95th percentile values of individual populations tested at each site. Uniform reporting of cut points has not been achieved. The purpose of this manuscript is to recommend appropriate decision values for Lp-PLA2, endorsed by a consensus panel of laboratorians and clinicians from the major laboratories where the test is performed. These coauthors possess considerable experience with assessment of cardiovascular risk marker decision values in general and are familiar with the validation of the Lp-PLA2 immunoassay and the Lp-PLA2 clinical studies conducted thus far. An ideal risk marker, studied in an ideal population, might yield a consistent cut point associated with a sudden increase in cardiovascular risk. While acknowledging that additional studies will be required to test and refine the recommended decision value, this article reviews the most current information with which to provide guidance to practicing clinicians regarding Lp-PLA2 levels. Since several studies have demonstrated increased risk associated with the second and third tertiles vs. the first tertile for Lp-PLA2, the 50th percentile cut point (235 ng/mL) is recommended as a conservative cut point associated with increased risk for cardiovascular disease. This cut point is not proposed as a treatment target, but rather as a level above which clinicians should consider a patient to be at higher risk for cardiovascular events, independent of established risk factors, high- and low-density lipoprotein cholesterol, and high-sensitivity C-reactive protein.",
author = "Lanman, {Richard B.} and Wolfert, {Robert L.} and Fleming, {James K.} and Jaffe, {Allan S} and Roberts, {William L.} and Warnick, {G. Russell} and McConnell, {Joseph P.}",
year = "2006",
month = "6",
doi = "10.1111/j.1520-037X.2006.05547.x",
language = "English (US)",
volume = "9",
pages = "138--143",
journal = "Preventive Cardiology",
issn = "1520-037X",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Lipoprotein-associated phospholipase A2

T2 - review and recommendation of a clinical cut point for adults.

AU - Lanman, Richard B.

AU - Wolfert, Robert L.

AU - Fleming, James K.

AU - Jaffe, Allan S

AU - Roberts, William L.

AU - Warnick, G. Russell

AU - McConnell, Joseph P.

PY - 2006/6

Y1 - 2006/6

N2 - Recently, several epidemiologic studies have demonstrated an association between plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) concentration and risk of subsequent cardiovascular events. Several major commercial and reference laboratories across the United States are now offering Lp-PLA2 testing for clinical use to evaluate cardiovascular risk and as a guide to intensity of therapy in individuals at intermediate risk for developing coronary heart disease. Each laboratory has established its own cut points, or "decision values," for Lp-PLA2, which vary from the 50th to the 95th percentile values of individual populations tested at each site. Uniform reporting of cut points has not been achieved. The purpose of this manuscript is to recommend appropriate decision values for Lp-PLA2, endorsed by a consensus panel of laboratorians and clinicians from the major laboratories where the test is performed. These coauthors possess considerable experience with assessment of cardiovascular risk marker decision values in general and are familiar with the validation of the Lp-PLA2 immunoassay and the Lp-PLA2 clinical studies conducted thus far. An ideal risk marker, studied in an ideal population, might yield a consistent cut point associated with a sudden increase in cardiovascular risk. While acknowledging that additional studies will be required to test and refine the recommended decision value, this article reviews the most current information with which to provide guidance to practicing clinicians regarding Lp-PLA2 levels. Since several studies have demonstrated increased risk associated with the second and third tertiles vs. the first tertile for Lp-PLA2, the 50th percentile cut point (235 ng/mL) is recommended as a conservative cut point associated with increased risk for cardiovascular disease. This cut point is not proposed as a treatment target, but rather as a level above which clinicians should consider a patient to be at higher risk for cardiovascular events, independent of established risk factors, high- and low-density lipoprotein cholesterol, and high-sensitivity C-reactive protein.

AB - Recently, several epidemiologic studies have demonstrated an association between plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) concentration and risk of subsequent cardiovascular events. Several major commercial and reference laboratories across the United States are now offering Lp-PLA2 testing for clinical use to evaluate cardiovascular risk and as a guide to intensity of therapy in individuals at intermediate risk for developing coronary heart disease. Each laboratory has established its own cut points, or "decision values," for Lp-PLA2, which vary from the 50th to the 95th percentile values of individual populations tested at each site. Uniform reporting of cut points has not been achieved. The purpose of this manuscript is to recommend appropriate decision values for Lp-PLA2, endorsed by a consensus panel of laboratorians and clinicians from the major laboratories where the test is performed. These coauthors possess considerable experience with assessment of cardiovascular risk marker decision values in general and are familiar with the validation of the Lp-PLA2 immunoassay and the Lp-PLA2 clinical studies conducted thus far. An ideal risk marker, studied in an ideal population, might yield a consistent cut point associated with a sudden increase in cardiovascular risk. While acknowledging that additional studies will be required to test and refine the recommended decision value, this article reviews the most current information with which to provide guidance to practicing clinicians regarding Lp-PLA2 levels. Since several studies have demonstrated increased risk associated with the second and third tertiles vs. the first tertile for Lp-PLA2, the 50th percentile cut point (235 ng/mL) is recommended as a conservative cut point associated with increased risk for cardiovascular disease. This cut point is not proposed as a treatment target, but rather as a level above which clinicians should consider a patient to be at higher risk for cardiovascular events, independent of established risk factors, high- and low-density lipoprotein cholesterol, and high-sensitivity C-reactive protein.

UR - http://www.scopus.com/inward/record.url?scp=33749249742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749249742&partnerID=8YFLogxK

U2 - 10.1111/j.1520-037X.2006.05547.x

DO - 10.1111/j.1520-037X.2006.05547.x

M3 - Article

VL - 9

SP - 138

EP - 143

JO - Preventive Cardiology

JF - Preventive Cardiology

SN - 1520-037X

IS - 3

ER -